ALKEM:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 3,003.60

Change

0.00 (0.00)%

Market Cap

INR 363.42B

Volume

0.16M

Average Target Price

INR 3,176.67 (+5.76%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. Alkem Laboratories Limited was founded in 1973 and is headquartered in Mumbai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR1,698.97B 70.51 33.42
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR1,081.41B 57.82 38.87
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR880.98B 41.43 21.10
CADILAHC:NSE Cadila Healthcare Limited

N/A

INR644.80B 34.94 20.26
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR604.04B 11.22 7.46
LUPIN:NSE Lupin Limited

N/A

INR554.27B 48.51 19.74
IPCALAB:NSE Ipca Laboratories Limited

N/A

INR274.10B 25.68 17.01
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR263.87B 26.90 17.56
APLLTD:NSE Alembic Pharmaceuticals Limite..

N/A

INR187.23B 15.67 11.71
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

N/A

INR176.37B 18.43 8.51

ETFs Containing ALKEM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.79% 28% F 37% F
Dividend Return 0.85% 30% F 44% F
Total Return 2.64% 31% F 38% F
Trailing 12 Months  
Capital Gain 18.86% 6% F 12% F
Dividend Return 1.11% 76% C 43% F
Total Return 19.96% 6% F 13% F
Trailing 5 Years  
Capital Gain 153.16% 73% C 81% B-
Dividend Return 6.07% 92% A- 62% D-
Total Return 159.23% 73% C 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 15.15% 48% F 71% C-
Dividend Return 0.64% 69% D+ 48% F
Total Return 15.79% 47% F 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 21.72% 100% A+ 91% A-
Risk Adjusted Return 72.68% 95% A 94% A
Market Capitalization 363.42B 91% A- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.70 54% F 45% F
Price/Book Ratio 4.95 37% F 19% F
Price / Cash Flow Ratio 62.12 12% F 7% F
EV/EBITDA 15.84 47% F 41% F
Management Effectiveness  
Return on Equity 22.57% 73% C 91% A-
Return on Invested Capital 16.63% 78% C+ 87% B+
Return on Assets 10.52% 77% C+ 92% A-
Debt to Equity Ratio 1.10% 69% D+ 76% C
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.35 84% B 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.